Zhang Chunyan, Yue Chanyu, Herrmann Andreas, Song Jieun, Egelston Colt, Wang Tianyi, Zhang Zhifang, Li Wenzhao, Lee Heehyoung, Aftabizadeh Maryam, Li Yi Jia, Lee Peter P, Forman Stephen, Somlo George, Chu Peiguo, Kruper Laura, Mortimer Joanne, Hoon Dave S B, Huang Wendong, Priceman Saul, Yu Hua
Department of Immuno-Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Department of Immuno-Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; Sorrento Therapeutics Inc. 4955 Directors PI, San Diego, CA 92121, USA.
Cell Metab. 2020 Jan 7;31(1):148-161.e5. doi: 10.1016/j.cmet.2019.10.013. Epub 2019 Nov 21.
Although obesity is known to be critical for cancer development, how obesity negatively impacts antitumor immune responses remains largely unknown. Here, we show that increased fatty acid oxidation (FAO) driven by activated STAT3 in CD8 T effector cells is critical for obesity-associated breast tumor progression. Ablating T cell Stat3 or treatment with an FAO inhibitor in obese mice spontaneously developing breast tumor reduces FAO, increases glycolysis and CD8 T effector cell functions, leading to inhibition of breast tumor development. Moreover, PD-1 ligation in CD8 T cells activates STAT3 to increase FAO, inhibiting CD8 T effector cell glycolysis and functions. Finally, leptin enriched in mammary adipocytes and fat tissues downregulates CD8 T cell effector functions through activating STAT3-FAO and inhibiting glycolysis. We identify a critical role of increased oxidation of fatty acids driven by leptin and PD-1 through STAT3 in inhibiting CD8 T effector cell glycolysis and in promoting obesity-associated breast tumorigenesis.